WAT · Insider Trading
Waters Corp
Every open-market purchase and sale reported by WAT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Heather Knight | Director | A | +57 | — |
| 2026-10-02 | Wei Jiang | Director | A | +57 | — |
| 2026-08-07 | Christopher A Kuebler | Director | MIXED | — | −$948.24K |
| 2026-08-07 | Christopher A Kuebler | Director | MIXED | — | −$948.24K |
| 2026-07-02 | Wei Jiang | Director | A | +67 | — |
| 2026-07-02 | Heather Knight | Director | A | +63 | — |
| 2026-06-25 | Robert L Carpio III | SVP Waters Analytical Sciences | F | −189 | −$69.78K |
| 2026-05-14 | Amol Chaubal | SVP & Chief Financial Officer | F | −239 | −$84.18K |
| 2026-04-07 | Jianqing Bennett | SVP Waters Adv. Diagnostics | F | −302 | −$91.84K |
| 2026-04-02 | Heather Knight | Director | A | +68 | — |
| 2026-04-02 | Wei Jiang | Director | A | +64 | — |
| 2026-03-18 | Wei Jiang | Director | Buy | +500 | +$144.73K |
| 2026-03-10 | Richard H Fearon | Director | Buy | +1,000 | +$306.34K |
| 2026-03-03 | Jianqing Bennett | SVP Waters Adv. Diagnostics | F | −410 | −$125.96K |
| 2026-03-03 | Amol Chaubal | SVP & Chief Financial Officer | F | −709 | −$217.83K |
| 2026-03-03 | Udit Batra | President and CEO | F | −3,417 | −$1.05M |
| 2026-02-27 | Flemming Ornskov | Director | A | +336 | — |
| 2026-02-27 | Linda Baddour | Director | A | +23 | — |
| 2026-02-27 | Daniel J. Brennan | Director | A | +23 | — |
| 2026-02-27 | Richard H Fearon | Director | A | +23 | — |
| 2026-02-27 | Claire Fraser | Director | A | +358 | — |
| 2026-02-27 | Pearl S Huang | Director | A | +23 | — |
| 2026-02-27 | Wei Jiang | Director | A | +23 | — |
| 2026-02-27 | Heather Knight | Director | A | +23 | — |
| 2026-02-27 | Christopher A Kuebler | Director | A | +23 | — |
| 2026-02-27 | Mark Vergnano | Director | A | +23 | — |
| 2026-02-27 | Udit Batra | President and CEO | A | +5,165 | — |
| 2026-02-27 | Amol Chaubal | SVP & Chief Financial Officer | A | +1,455 | — |
| 2026-02-27 | Jianqing Bennett | SVP Waters Adv. Diagnostics | A | +986 | — |
| 2026-02-27 | Robert L Carpio III | SVP Waters Analytical Sciences | A | +997 | — |
| 2026-02-06 | Udit Batra | President and CEO | MIXED | +6,848 | −$82.16K |
| 2026-02-06 | Amol Chaubal | SVP & Chief Financial Officer | MIXED | +1,826 | −$21.86K |
| 2026-02-06 | Jianqing Bennett | SVP TA Instruments Division | MIXED | +1,342 | −$16.21K |
| 2026-02-06 | Robert L Carpio III | SVP, Waters Division | F | −38 | −$14.32K |
| 2026-01-05 | Heather Knight | Director | A | +366 | — |
| 2026-01-05 | Wei Jiang | Director | A | +366 | — |
| 2026-01-05 | Flemming Ornskov | Director | A | +307 | — |
| 2026-01-05 | Linda Baddour | Director | A | +307 | — |
| 2026-01-05 | Daniel J. Brennan | Director | A | +307 | — |
| 2026-01-05 | Richard H Fearon | Director | A | +307 | — |
| 2026-01-05 | Pearl S Huang | Director | A | +307 | — |
| 2026-01-05 | Christopher A Kuebler | Director | A | +307 | — |
| 2026-01-05 | Mark Vergnano | Director | A | +307 | — |
| 2025-11-07 | Christopher A Kuebler | Director | MIXED | +2,443 | −$10 |
| 2025-10-02 | Wei Jiang | Director | A | +72 | — |
| 2025-10-02 | Heather Knight | Director | A | +77 | — |
| 2025-07-01 | Wei Jiang | Director | A | +68 | — |
| 2025-07-01 | Heather Knight | Director | A | +68 | — |
| 2025-06-26 | Robert L Carpio III | SVP, Waters Division | F | −134 | −$46.47K |
| 2025-05-14 | Amol Chaubal | SVP & Chief Financial Officer | F | −239 | −$87.63K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Udit Batra | President and CEO | 33,140 | $14.96M |
| Christopher A Kuebler | Director | 21,434 | $9.68M |
| Amol Chaubal | SVP & Chief Financial Officer | 7,834 | $3.54M |
| Jianqing Bennett | SVP Waters Adv. Diagnostics | 6,532 | $2.95M |
| Flemming Ornskov | Director | 5,271 | $2.38M |
| Mark Vergnano | Director | 4,540 | $2.05M |
| Wei Jiang | Director | 3,630 | $1.64M |
| Robert L Carpio III | SVP Waters Analytical Sciences | 3,426 | $1.55M |
| Richard H Fearon | Director | 3,302 | $1.49M |
| Pearl S Huang | Director | 3,276 | $1.48M |
| Linda Baddour | Director | 2,899 | $1.31M |
| Daniel J. Brennan | Director | 1,355 | $611.65K |
| Heather Knight | Director | 1,337 | $603.95K |
| Claire Fraser | Director | 489 | $220.73K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the WAT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.